Journal Home
Search for

Volume 45, Issue 1, Pages 70-76 (July 2009)


View previous. 13 of 21 View next.

Hyperprolactinemia-Related Adverse Events Associated with Antipsychotic Treatment in Children and Adolescents

Jeanette M. Jerrell, Ph.D.aCorresponding Author Informationemail address, Janice Bacon, M.D.b, Judith T. Burgis, M.D.b, Seema Menon, M.D.b

Received 25 February 2008; accepted 24 November 2008. published online 09 March 2009.

Abstract 

Purpose

To characterize factors related to the development of hyperprolactinemia and the ensuing reproductive/sexual adverse events in children and adolescents treated with antipsychotic and other psychotropic agents, and the additional risk posed for those with comorbid obesity, metabolic, or endocrine disorders.

Methods

A retrospective cohort design evaluating medical and pharmacy claims from South Carolina's Medicaid program was used to compare incidence rates for sexual/reproductive adverse events in 4140 children and adolescents who were newly prescribed one of six atypical or two conventional antipsychotic medications, and a random sample of 4500 children not treated with psychotropic medications, January 1998 to December 2005. Logistic and Cox Proportional Hazards regression and Kaplan-Meier survival analysis were performed.

Results

The treated cohort was not significantly more likely to evince hyperprolactinemia-related disorders than the control sample, but females and adolescents 13 and older were. Incident reproductive/sexual conditions were more likely for females (odds ratio [OR] = 9.52; confidence interval [CI] = 7.63–11.90), adolescents (OR = 3.91; CI = 3.25–4.70), those also taking selective serotonin reuptake inhibitors (SSRIs) (OR = 2.04; CI = 1.56–2.37) or valproic acid derivatives (OR = 1.29; CI = 1.03–1.64), and those with comorbid obesity/weight gain (OR = 1.92; CI = 1.56–2.37), metabolic (OR = 1.41; CI = 1.12–1.78), or endocrine disorders (OR = 2.76; CI = 1.98–3.84).

Conclusion

In this treated cohort, female adolescents exposed to SSRIs or valproic acid derivatives and those with comorbid obesity, metabolic, or endocrine disorders while taking antipsychotics were at higher risk of developing hyperprolactinemia and ensuing sexual/reproductive adverse events.

a Department of Neuropsychiatry, University of South Carolina School of Medicine, Columbia, South Carolina

b Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, South Carolina

Corresponding Author InformationAddress correspondence to: Jeanette M. Jerrell, Ph.D., Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, 3555 Harden Street Ext., CEB 301, Columbia, SC 29203.

PII: S1054-139X(08)00679-4

doi:10.1016/j.jadohealth.2008.11.010


View previous. 13 of 21 View next.